SCIENTEX

SCIENTX
End-of-day quote. End-of-day quote  - 11/24
12.18MYR -3.18%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: July 2020 2021
Net sales1 3 5194 093
EBITDA1 657733
Operating profit (EBIT)1 549611
Operating Margin 15,6%14,9%
Pre-Tax Profit (EBT)1 544611
Net income1 390450
Net margin 11,1%11,0%
EPS2 0,760,87
Dividend per Share2 0,230,26
Last update 09/18/202010/05/2020
1 MYR in Million
2 MYR
Estimates
Finances - Leverage
Fiscal Period: July 2020 2021
Net Debt --
Net Cash position --
Leverage (Debt / EBITDA) --
Free Cash Flow --
ROE (Net Profit / Equities) 16,9%16,7%
Shareholders' equity1 2 3112 689
ROA (Net Profit / Asset) 9,28%9,45%
Assets1 4 2054 759
Book Value Per Share2 4,975,96
Cash Flow per Share --
Capex1 79,4200
Capex / Sales 2,26%4,89%
Last update 09/18/202010/05/2020
1 MYR in Million
2 MYR
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 6 295 M MYR -
Valuation 2021e 2022e
P/E ratio (Price / EPS) 14,0x 12,5x
Capitalization / Revenue 1,54x 1,40x
Yield (DPS / Price) 2,17% 2,44%
Price to book (Price / BVPS) 2,04x 1,84x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 14,9% 15,0%
Operating Leverage (Delta EBIT / Delta Sales) 0,68x 1,05x
Net Margin (Net Profit / Revenue) 11,0% 11,2%
ROA (Net Profit / Asset) 9,45% 9,30%
ROE (Net Profit / Equities) 16,7% 16,4%
Rate of Dividend 30,4% 30,4%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   4,89% 4,45%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 1,16x 1,21x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend